secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001193125-22-169686
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports PC14586 Phase 1 data: 32% ORR at high doses, responses in 6 tumor types
--------------------------------------------------------------------------------

- Overall response rate (ORR) 32% (8/25) in patients receiving daily dose ≥1150 mg; 24% (8/33) across all doses.
- Partial responses observed in breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancers.
- Maximum tolerated dose reached at 1500 mg twice daily; common AEs included nausea, vomiting, AST/ALT increases.
- Phase 2 portion of PYNNACLE study expected to start early 2023; data provide proof of concept for p53 reactivation.
- Data presented at ASCO 2022 by MD Anderson investigator; first-in-class small molecule targeting p53 Y220C mutation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312522169686/0001193125-22-169686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312522169686/d274688d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-169686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer